Lonza forms development manufacturing agreement with Genmab

Lonza forms development and manufacturing agreement with Genmab

11:40 PM, 24th October 2011
Lonza forms development and manufacturing agreement with Genmab
Stephan Kutzer, COO, Lonza Custom Manufacturing.

 

BASEL, SWITZERLAND: Lonza forms a new development and manufacturing agreement with Genmab A/S. This agreement secures a development and cGMP manufacturing plan for Genmab to produce a novel ADC product targeting tissue factor (TF). Financial details of the agreement were undisclosed.

The use of ADCs as therapeutic agents is becoming an important therapeutic approach for the treatment of various cancers. This project utilizes Lonza’s experts in both antibody production and drug conjugation, providing a harmonized solution for Genmab’s technology.

Lonza will initiate process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF in its Slough, UK facility. This antibody has been expressed by Genmab A/S in Lonza’s GS Gene Expression System. The naked antibody will be conjugated by Lonza at its ADC plant in Visp, CH to a cytotoxic drug in order to form the antibody drug conjugate HuMax-TF.

“The agreement with Genmab A/S on this novel product leverages Lonza’s experience in both high potency synthetic chemistry and mammalian biopharmaceutical manufacturing. Lonza is uniquely positioned to offer complete development and manufacturing services for the production of antibody drug conjugates like HuMax-TF ADC,” said Stephan Kutzer, COO, Lonza Custom Manufacturing.

(C) WOC News

 

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Scotts and Marrone to collaborate for agricultural biopesticides R&D

  MARYSVILLE/DAVIS, US: Scotts Miracle-Gro Co and Marrone Bio Innovations will collaborate for research and development to provide consumers wit ...

Read more
Saltigo to build new capacity for potent APIs in US

  LANGENFELD, GERMANY: Saltigo GmbH, a Lanxess subsidiary, recently announced two important strategies in its custom manufacturing services. Fi ...

Read more
Air Liquide signs new contract with Posco in South Korea

PARIS, FRANCE: Air Liquide has signed a contract with Posco E&C, the Engineering and Construction division of Posco, to design and build two large ...

Read more
BASF to build tert.-Butylamine plant in Nanjing

  NANJING/JI’NING, CHINA: BASF will build a production plant to produce tert.-Butylamine (tBA) in Nanjing, China. The facility will be who ...

Read more
ICL acquires SQM’s 50 per cent share in Nutrisi Holdings

TEL AVIV, ISRAEL: Israel Chemicals Ltd (ICL) has agreed with SQM, a Chilean company with whom ICL currently owns Nutrisi Holdings, to purchase SQM&r ...

Read more
Researchers block morphine’s itchy side effect

  ST LOUIS, US: Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. Th ...

Read more